ArticleBioImpacts : BI2011
Smart multifunctional theranostics: simultaneous diagnosis and therapy of cancer.
Article in BioImpacts : BI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Chitosan Nanoparticles: Approaches to Preparation, Key Properties, Drug Delivery Systems, and Developments in Therapeutic Efficacy.AAPS PharmSciTech · 2025Review
- Allosteric ligand-driven smart nanoconjugates for mutation-selective EGFR targeting: A precision approach to overcoming tyrosine kinase inhibitor resistance.BioImpacts : BI · 2025Review
- Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review.Micromachines · 2022Review
- TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.BioImpacts : BI · 2022Article
- Editorial: Target-Triggered Nanoparticles for Tumor Diagnosis and Therapy.Frontiers in chemistry · 2021Article
- Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors.Frontiers in chemistry · 2020Review
- FMSP-Nanoparticles Induced Cell Death on Human Breast Adenocarcinoma Cell Line (MCF-7 Cells): Morphometric Analysis.Biomolecules · 2018Article
- Mucin-1 aptamer-armed superparamagnetic iron oxide nanoparticles for targeted delivery of doxorubicin to breast cancer cells.BioImpacts : BI · 2018Article
- Importance of Evaluating Dynamic Encapsulation Stability of Amphiphilic Assemblies in Serum.Biomacromolecules · 2017Article
- Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy.BioImpacts : BI · 2017Review
- Stimuli-responsive chitosan-based nanocarriers for cancer therapy.BioImpacts : BI · 2017Review
- Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.Journal of nanobiotechnology · 2015Article
- A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination.BioImpacts : BI · 2015Article
- Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies.BioImpacts : BI · 2015Article
- Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer.BioImpacts : BI · 2014Review
- Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer.International journal of nanomedicine · 2014Article
- Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines.BioImpacts : BI · 2014Review
- Non-metallic nanomaterials in cancer theranostics: a review of silica- and carbon-based drug delivery systems.Science and technology of advanced materials · 2013Review
- Targeted fluoromagnetic nanoparticles for imaging of breast cancer mcf-7 cells.Advanced pharmaceutical bulletin · 2013Article
- Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.BioImpacts : BI · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical applications of advanced nanomedicines such as PEGylated liposomal doxorubicin and paclitaxel-albumin bioconjugates have significantly improved the cancer treatment strategies. However, these pharmaceuticals lack early detection and single cell tracking capabilities. Thus, engineering of smart multifunctional theranostics appear to be our next step for simultaneous diagnosis and therapy of cancer. Clinical translation of multifunctional theranostics appears to be dependent upon specificity of cancer biomarkers, biocompatibility of components used for formulation, and advancement of bioconjugation techniques. While many cancer biomarker candidates often fail to be used for clinical diagnosis/therapy because of their nonspecific functional expression in normal tissues, biocompatibility of materials used for bioconjugation also needs to be approved. All these issues need to be fully addressed prior to the translation of smart multifunctional cancer theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.